Please login to the form below

Not currently logged in
Email:
Password:

study

This page shows the latest study news and features for those working in and with pharma, biotech and healthcare.

Menlo slumps as itching drug fails mid-stage trial

Menlo slumps as itching drug fails mid-stage trial

study. The reversal wiped out a steady series of gains for the stock since it announced a merger with Foamix Pharmaceuticals, despite Menlo’s insistence that the failure wouldn’t disrupt ... At the end of the study period, 37.9% of patients in the

Latest news

More from news
Approximately 4 fully matching, plus 3,609 partially matching documents found.

Latest Intelligence

  • BRIC markets BRIC markets

    According to a recent study, although per capita healthcare spending is still highest in G7 nations, the percentage share of global expenditure coming from developed countries has fallen from 65% in ... According to a 2018 study, average revenues

  • New strategic blueprint: the new first questions New strategic blueprint: the new first questions

    Rapid sell-offs, realignments and top pharma spin-offs left phase 3 studies incomplete or froze active marketing and promotion of commercialised drugs.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Although the drugmaker appealed the decision, it was unsuccessful. The company’s cause wasn’t helped by an FDA study which claimed to have found ‘sub-trace’ levels of asbestos in

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    One study suggests nearly $60bn in savings would be achievable over the next decade, but only if the US can figure out a way to overcome biosimilar market barriers. ... The FTC has also made legal arguments against the practice of denying drug samples to

  • Tackling antimicrobial resistance on multiple fronts Tackling antimicrobial resistance on multiple fronts

    Recent studies, like that of Public Health England, confirm that knowing when to use antibiotics is becoming even more important and while behaviours are shifting in the right direction, they also

More from intelligence
Approximately 4 fully matching, plus 491 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 55 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 33 fully matching, plus 380 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics